PRISM 2

Psychiatric ratings using intermediate stratified markers 2

Summary

Currently, neurological disorders are diagnosed primarily on the basis of patients’ symptoms, and not on the causes of the disease. Furthermore, many symptoms appear in a number of diseases, yet we don’t always know if the causes of a given symptom are the same across diseases or not. Pinpointing the underlying causes of symptoms and diseases is essential if we are to develop targeted treatments for these complex conditions.

IMI’s PRISM project focused on social withdrawal, a common early symptom of many neurological disorders. PRISM shed new light on the underlying causes of social withdrawal in schizophrenia and Alzheimer’s disease, including some of the genes involved as well as a neural network. Interestingly, the neural network involved in social withdrawal appears to be the same in both diseases. The team also developed an early version of a suite of tests, including scans, blood tests and smartphone monitoring, which could potentially make it easier to diagnose conditions, indicate the brain mechanisms involved, and identify targets for new treatments.

The goal of the PRISM 2 project is to build on the achievements of the original PRISM project. Specifically, it aims to validate PRISM’s findings on social withdrawal in schizophrenia and Alzheimer’s disease, and investigate whether they also apply to major depressive disorder.

Ultimately, the work of PRISM 2 should ensure that these findings will result in more accurate diagnoses and treatments for people with Alzheimer’s disease, schizophrenia and major depressive disorder.

Participants

  Show participants on map
EFPIA companies
  • Boehringer Ingelheim Internationalgmbh, Ingelheim, Germany
  • Psychogenics Inc, Tarrytown, United States
Universities, research organisations, public bodies, non-profit groups
  • Academisch Ziekenhuis Leiden, Leiden, Netherlands
  • Alma Mater Studiorum - Universita Di Bologna, Bologna, Italy
  • Consorcio Centro De Investigacion Biomedica En Red M.P., Madrid, Spain
  • Rijksuniversiteit Groningen, Groningen, Netherlands
  • Stichting Buro Ecnp, Utrecht, Netherlands
  • Stichting Radboud Universitair Medisch Centrum, Nijmegen, Netherlands
  • Stichting Vumc, Amsterdam, Netherlands
Small and medium-sized enterprises (SMEs) and mid-sized companies (<€500 m turnover)
  • Biotrial, Rennes, France
  • Concentris Research Management GMBH, Fürstenfeldbruck, Germany
  • P1vital Limited, Wallingford, United Kingdom
  • Sbgneuro LTD, Thame, United Kingdom
Associated partners
  • Cohen Veterans Bioscience Inc, Cambridge, United States
Third parties
  • P1vital Products Limited, Wallingford, United Kingdom

Participants
NameIHI funding in €
Academisch Ziekenhuis Leiden270 000
Alma Mater Studiorum - Universita Di Bologna25 000
Biotrial174 690
Concentris Research Management GMBH260 000
Consorcio Centro De Investigacion Biomedica En Red M.P.499 976
P1vital Limited815 786
Rijksuniversiteit Groningen1 028 125
Sbgneuro LTD175 000
Stichting Buro Ecnp50 000
Stichting Radboud Universitair Medisch Centrum25 000
Stichting Vumc436 870
 
Third parties
NameFunding in €
P1vital Products Limited220 459
 
Total Cost3 980 906